酸化還元特性を持つ膜小胞によるバイオフィルム活性の制御

目前用于生产和药物测试的电化学反应器系统涉及的体积相对较大，使得这些系统无法高通量筛选潜在的抗菌素。我们使用丝网印刷电极或多孔电极系统，需要最少的样品和抗菌剂。这种利用病原体的电活动的系统可以快速追踪抗生物膜药物的发现，因为可以快速筛选出大量化合物。这一概念可以作为一种普遍适用的技术，用于评估抗菌剂的疗效，以及选择适当的药物或治疗方案。我们的工作将EET领域的边界扩展到其他利基领域，如人类病原体。在人类病原体中发现的EET基因的同源基因存在于数百个物种中，因此EET活性可能发生在进化上不同的细菌亚群中。因此，我们的研究可以通过利用目前在广泛的电活性病原体中的生产能力来帮助筛选抗菌剂对生物被膜活性的影响。

The electrochemical reactor systems currently used for current production and drug testing involve relatively large volumes, making these systems infeasible for high-throughput screening of potential antimicrobials. We used screen-printed electrodes or multi-well electrode systems that require minimum amounts of sample and antimicrobials. Such systems that exploit the electrogenic activity of pathogens could fast-track the discovery of antibiofilm drugs, as a large library of compounds could be rapidly screened. This concept could serve as a generally applicable technology for evaluating the efficacy of antimicrobials, as well as the selection of appropriate drugs or treatment regimens. Our works extended the boundaries of EET field to other niches such as human pathogens. The orthologues of the identified EET genes in human pathogens are present in hundreds of species, thus EET activity likely occurred in an evolutionarily diverse subset of bacteria. Consequently, our research can help screen the effects of antimicrobials on biofilm activity by employing the current producing capability in wide range of electroactive pathogens.